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Evaluating patients' preferences for multiple myeloma
therapy, a Discrete-Choice-Experiment
Messung von Patientenpräferenzen bei der Therapie des Multiplen
Myeloms, ein Discrete-Choice-Experiment
Abstract
Background:Whilethereisanincreasingemphasisonpatientempower-
ment and shared decision making, patients’ preferences for attributes
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associated with their treatment still need to be measured and con-
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sidered.Inthepresentstudy,patients'preferencesregardingtreatment
of multiple myeloma (MM) were explored using direct assessment and
a Discrete-Choice-Experiment (DCE). 1 GEB: Gesellschaft für
Empirische Beratung mbH Patients and methods: After reviewing the literatureaboutpreferences
of myeloma patients we conducted a qualitative study with three focus (Empirical Consulting),
Denzlingen, Germany groups consisting of six to eight MM-patients each. In order to achieve
content validity, we aimed at collecting all relevant factors for an ideal
MM-treatment. In a subsequent quantitative study phase, data was
collected in an online or paper-pencil self-completed questionnaire. It
included sociodemographic data, self-rated health (SF12v2 variation)
and patients preferences of therapy characteristics using direct meas-
urement (16 items on a five-point Likert-scale) as well as a Discrete-
Choice-Experiment (DCE, eight pairs with eight characteristics).
Results: 282 patients answered the questionnaire; 46% female, age:
mean 62 yrs (SD=10 years), duration of MM: 5 yrs (SD=3.8 years).
Direct measurement showed effectiveness aspects (i.e. high effective-
ness, long lasting effects, max. prolonged life expectancy) and further
treatment options in the first places, followed by maximal prolonged
life expectancy, minor side effects and therapy-free-intervals. In the
DCE,alternativeswithfurthertreatmentoptions,longerlifeexpectancy,
"not always think of the disease" and therapy-free-intervals were more
likely to be chosen, giving thus similar results.
Conclusion: Besides prolongation of life expectancy and effectiveness
of treatment, further treatment options are of foremost importance to
multiple myeloma patients. In addition, therapy-free intervals as well
as an improved emotional quality of life (“Not always think of the dis-
ease”) are valued as very important.
ThecombinationofdirectassessmentofimportanceandDCEisavalid
combined survey technique for eliciting preferences of patients with
multiple myeloma. The former ensures content validity (the possibility
to measurea longer list of potentiallyimportant aspects),the latter has
theadvantagetocombinepositiveandnegativetherapycharacteristics
andtoavoidtheproblemofceilingeffectsand“all-is-important”results.
Keywords: multiple myeloma, patient preference, Discrete-Choice-
Experiment (DCE), direct assessment
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Hintergrund:MitdemwachsendenFokusaufdieBeteilungvonPatienten
an Therapieentscheidungen im Sinne des „Shared decision making“
isteswichtig,diePatientenpräferenzenhinsichtlichvonTherapieeigen-
schaften zu erfassen und zu berücksichtigen. Ziel der vorliegenden
Studie war es, mittels direkter Bewertung und Discrete-Choice-Experi-
ments (DCE) diejenigen Parameter der Therapie zu erfassen, die Pati-
enten mit Multiplem Myelom (MM) am wichtigsten sind.
Patienten und Methoden: Nach Durchsicht der relevanten Literatur
führten wir eine qualitative Vorstudie auf Basis dreier Fokus-Gruppen
mit jeweils sechs bis acht MM-Patienten durch. Um die Inhaltsvalidität
des Fragebogens für die quantitative Hauptstudie abzusichern, zielten
wir darauf ab, alle relevanten Faktoren einer idealen MM-Behandlung
aus Patientensicht zu erfassen. Der Fragebogen (online sowie Papier-
version) der Hauptstudie beinhaltete soziodemographische Angaben,
Fragen zum Gesundheitszustand (SF12v2 SOEP Variante) und Fragen
zur direkten Messung der Präferenzen (16 Items, fünfstufig Likert-ska-
liert) sowie ein Discrete-Choice-Experiment mit acht Paaren mit je acht
Therapieeigenschaften.
Ergebnisse: Die Auswertung basiert auf 282 Patienten; 46% weiblich,
Durchschnittsalter62Jahre(SD=10Jahre),mittlereErkrankungsdauer
fünf Jahre (SD=3,8). In der direkten Präferenzabfrage erachteten die
BefragtendieParameterWirksamkeitundweitereBehandlungsoptionen
alsamwichtigsten,gefolgtvonverlängerterLebenserwartung,geringen
Nebenwirkungen und therapiefreien Intervallen. Im DCE bevorzugten
Patienten Behandlungsalternativen signifikant, die eine oder mehrere
der folgenden Eigenschaften beinhalteten: weitere Behandlungsoptio-
nen, verlängerte Lebensdauer, "nicht immer an die Krankheit denken
müssen“ sowie therapiefreie Intervalle. Damit ergeben sich ähnliche
Präferenzen wie in der direkten Messung.
Schlussfolgerung:NebeneinerVerlängerungderLebenserwartungund
derWirksamkeitderBehandlungistesMM-Patientenbesonderswichtig,
dasseineTherapieweitereBehandlungsoptionenimVerlaufderErkran-
kung offen hält. Darüber hinaus sind Therapiepausen und eine verbes-
serteemotionaleLebensqualität(„NichtimmerandieKrankheitdenken
müssen“)vonBedeutung.MethodischistdieKombinationderdirekten
BewertungmiteinerwahlbasiertenMessungwiedemDCEfürdieErhe-
bung der Präferenzen von MM-Patienten bezüglich der Therapie nach
unseren Ergebnissen sinnvoll und fruchtbar. Die direkte Methode kann
mehrAspekteberücksichtigen(Inhaltsvalidität),währenddasDCEdurch
Vorlage von Kombinationen positiver wie negativer Eigenschaften eine
klarere Abstufung der Präferenzen erzeugt und Deckeneffekte sowie
„alles-ist-wichtig“-Ergebnisse vermeidet.
Schlüsselwörter:MultiplesMyelom,Patientenpräferenz,Discrete-Choice-
Experiment (DCE), direkte Bewertung
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Introduction
Multiple myeloma (MM) is a B-cell malignancy affecting
immunoglobulin-producing plasma cells and accounts
forapproximately15%oflymphato-hematopoieticcancers
(LHC) [1]. The disease is a subtype of the heterogeneous
groupoflymphoma(ICDC.90).Themajorclinicalfeatures
of this relatively rare cancer result from the abnormal
accumulation of malignant plasma cells within the bone
marrow and other tissues. Multiple myeloma primarily
affects older adults with the median age at diagnosis of
65 years [2].
IntheEuropeanUnion,theincidenceofmultiplemyeloma
is 5.72 per 100,000 people, about 27,500 new patients
develop the disease each year in Europe and 3500 in
Germany[3].Currently,around70,000patientsareliving
withmultiplemyelomaintheEuropeanUnionand12,000
in Germany. Multiple myeloma is slightly more common
in men than women [4].
Despite advances in systemic and supportive therapies,
multiple myeloma has remained an incurable disease.
The present study assesses the therapy-related expecta-
tionsandperceptionsofMM-patients.Contrarytoclinical
trials concerning mainly efficacy, the primary goal of this
studywasthecomprehensiveevaluationofpreferablyall
relevant aspects of treatment quality from the patients’
perspective such as effectiveness, quality of life, further
treatmentoptionsandtherapy-freeintervals.Secondary,
we were interested how the study participants would
judge the relevance of these criteria.
Methods
The study was divided into two parts:
• aqualitativeparttoelicitandcollectrelevantattributes
• a quantitative main study to assess the patients'
preferences
Qualitative study
Prior to the main study, we performed a qualitative study
toidentifyimportantaspectsofanidealmultiplemyeloma
treatment.Patientadvocacygroups„Arbeitsgemeinschaft
Plasmozytom/MultiplesMyelom(APMM)“and„Deutsche
Leukämie-Hilfe(DLH)“askedpatientstoparticipate.They
were interviewed in three focus groups (six to eight pa-
tientseach).Studygoalswereexplainedtoallparticipants
and all gave written informed consent for their participa-
tion. On the basis of literature research and the results
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of these focus groups 18 MM-therapy aspects were se-
lected for the main study (Table 1). Using this material,
we developed a questionnaire, which was administered
to 25 patients in a pretest. Based on the results of the
pretest we finalised the questionnaire.
Main study
The main study was performed as an anonymous survey
frommidofMayuntilendofJuly2007usingeitheronline
or paper questionnaires. Patients were contacted either
inwritinganddistributingthepaper-basedquestionnaire
version with stamped addressed envelopes, or via
email/internet. Both methods were used since older pa-
tients might not want to use the online version. Patient
advocacy groups helped in distributing paper-based
questionnaires and the link to the online version among
their regional affiliations. No personal data such as ad-
dresses, names or phone numbers were collected.
The questionnaire encompassed three main domains:
• PartA:Sociodemographiccharacteristics:age,gender,
educational level, household type (living alone or to-
gether with someone), duration of previous therapy,
member of patient advocacy group (Table 2)
• Part B: Current health status (Health related Quality
of Life (QoL), SF12v2, German version of the SOEP,
SozioOekonomisches Panel) [5], several questions
concerning utilization of medical care (medical treat-
mentinlastthreemonths,nightsinhospitalinlast12
months; Table 2)
• Part C: assessment of importance of MM-therapy
characteristics
C1: Direct assessment of importance of 16 items
(five-point Likert scale; Table 3)
•
C2: Discrete-Choice-Experiment (DCE) for eliciting
patients preferences using eight pairs with eight
characteristics (Table 4 and Table 5)
•
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Discrete-Choice-Experiments, also known as conjoint
analysis [6], are an attribute-associated measure of be-
nefit that is based on the assumptions that firstly,
healthcare interventions, services, or policies can be de-
scribed by their characteristics (or attributes) and
secondly,anindividuals’valuationdependsonthelevels
of these characteristics [7], [8]. In DCEs patients are
asked several times to choose between the alternatives
presented and described by their attributes; DCEs are
therefore often called choice-based measures.
Sincethequestionnaireinthisstudywasalsodistributed
asapaper-basedversion,weconductedarelativesimple
DCE technique with eight pair decisions, each with eight
attributes. Respondents had to choose eight times
betweenalternativeAorB.Theattributesandtheirlevels
are given in Table 4, an example for a choice between
two alternatives is given in Table 5.
Statistical analysis
For statistical data analysis, we used variance analysis,
regression analysis, factor analysis, and random effect
probitandlogitmodelsfortheDCE.Allstatisticalanalyses
were done by SPSS and STATA. The p-value <0.05 (two-
sided) was considered as being statistically significant.
Results
Patients Characteristics (Part A)
Between May and June 2007, 282 patients completed
thequestionnaires.54%answeredviapaperversionand
46% online. We could not evaluate a participation rate,
sincetheinvitationtoparticipationwaswidelyspreadvia
internet and email and therefore, the numberof patients
reached is unknown. 46% of the study participants were
female, 54% male; the huge majority is living together
with anotherperson,only16% live alone.Comparedwith
external data from cancer registries, the patients in our
study were younger: age at diagnosis (ICD: C.90) in re-
gistry Rhineland-Palatinate = 67 years (median) vs. first
therapy in this study = 62 years (median) [9]. 16% of the
patients were treatment-naive. Only patients, who previ-
ously had received treatment, answered the questions
abouttherapy,useofhealthcaresystemandpreferences
(N=238). Approximately 75% of the respondents were
currently members of patient advocacy groups. Other
baseline characteristics are listed in Table 2.
Self-rated health and use of health care
(Part B)
As expected, the MM-patients report a health status (as-
sessed with SF12 v2, SOEP version) that is distinctly be-
lowthegeneralpopulation.Themeanvalueof41.6points
(±8.6 standard deviation) for the physical health scale
(whichisameanvalueof0.84standarddeviationsbelow
the German average) lies farther below the norm value
fixed at a mean of 50 points (SD=10) than the value for
the mental health scale (mean 46.2 points, ±11.0
standarddeviation)comparedto50(SD=10)inthenorm
population.Nearlyallrespondentshaveseenaphysician
within the last three months (N=229 out of 230 valid
answers). The average number of disease-related visits
was 9.2 (approx. three visits/months; SD=14.2; range
0–150;medianfivevisits).60%ofthestudyparticipants
stayed at least one night in hospital during the last year
(approx.1.5nights/month;SD=27.0,range0–150;mean
19.3 nights, median eight nights).
Relevance of therapy characteristics:
Direct assessment and DCE (Part C)
Preferencesinthedirectassessment(PartC1)
In part C1, respondentshad to rate the importanceof 16
therapy characteristics using a five-point Likert-Scale,
rangingfrom“veryimportant“(100points)to“notimport-
ant“ (0 points) (Table 3).
Asdemonstratedin Figure1, allitemsconcerningquality
of treatment are of relatively high importance for the pa-
tients (given is the mean and the 95% confidence inter-
val). This is not surprising, since only aspects were
presented, that were rated as important according to the
literature and the qualitative study/focus groups. The
most relevant aspects have mean values ≥ 90 points.
PreferencesintheDiscrete-Choice-Experiment
(DCE) (Part C2)
DCEs are limited to the use of only a few characteristics.
It is very important to cover all the relevant fields when
selectingtheitemsfortheDCE.Fromtheliteraturereview
and the focus groups we learned that four major prefer-
ence dimensions from myeloma patients' perspective
are:
• Medical effectiveness aspects (like prolonged life ex-
pectancy, effectiveness and long duration of effect)
• Side effects
• Quality of life (in the three subdimensions social,
physical and emotional)
• Flexibilityinthesenseofbreaksintherapyandfurther
treatment options
Uponthisbasis,weaggregatedthepatients’preferences
frompartC1intoeightcharacteristics(asshowninTable
4 and Table 5) trying to cover all relevant dimensions. 16
virtualtherapiescombiningtheeightcharacteristicswere
generated at random. These 16 therapies were then
randomly combined to eight pairs with alternative A and
B each. This approach created varying decision options:
some choices were relatively simple because one altern-
ativewasinalmostallaspectsapparentlybetterthanthe
other. On the contrary, in difficult decisions the advant-
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Figure 1: Direct assessment: Importance of 16 therapy aspects (mean values; 95% CI)
ages and disadvantages were mostly equally distributed
which made the alternatives more equivalent and the
choicemoredifficult.Asanexample,Table5depictspair
3 where advantages of alternative B in the attributes 1,
2 and 3 are facing disadvantages in the attributes 6 and
8; in the attributes 4, 5 and 7, both alternatives are
equivalent (54% of patients chose alternative B, 46% al-
ternative A).
The chosen attributes and their 2 or 3 levels were effect-
coded for the overall analyses of all eight pair comparis-
ons. In general, the level signing the positive pole of an
attribute was coded positive (e.g. physical quality of life:
positive pole characteristic “not limited“, negative pole
“limited“). There was no a priori hypothesis concerning
the evaluation of the poles at item 7 “Therapy applied by
the physician or self-application”; here self-application
was coded as plus, applied by the physician coded as
minus.
In total, there were 1,797 valid observations. Some of
the respondents did evaluate no or not all pairs. On aver-
age, out of 232 respondents who finished at least one
pair comparison, 7.7 pairs were available (range 1–8).
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Table 5: Example for Discrete-Choice-Experiment (DCE); pair comparison No. 3
We created a random effects probit model which takes
intoaccountthepartialdependencyofobservationsfrom
the same person concerning the parameter estimation
(as shown in a highly significantchi bar test, this is advis-
able for our data).
For some levels and attributes the model does not give
a valid estimator due to collinearity problems. This was
true for the mid category of “Life expectancy” (item 1),
thehighestcategoryoftheparameter“Sideeffects“(item
2),themidcategoryoftheparameter“Therapyintervals“
as well as for the dichotomous attribute “Social quality
of life” (item 6).
Askingforpracticabilityapproximatelyevery10threspond-
ent rated the pair comparisons of the DCE as “very diffi-
cult“toaccomplish,18%as“ratherdifficult“,38%“partly
difficult, partly not”, 28% “rather not difficult”, and 7%
had no difficulties at all.
Estimated coefficients and their standard errors are
shown in Table 6. All but one of the attributes were stat-
istically significant predictors of the model of patient
preference. The attribute “Further treatment options”
(item 8) was the most important, closely followed by
“maximal prolonged life expectancy” (item 1). Items of
the psychological quality of life as “Not always think of
thedisease”(item5)and“Therapy-freeintervalspossible”
(item 3) were also relevant aspects for preferring a
treatment.Lessimportantbutstillstatisticallysignificant
were the items “Self-application of the treatment” (item
7) and “Physical well-being” (item 4). Characteristics of
side effects (item 2) did not play a significant role.
Based on the proportional distribution of the items’ im-
portance, and distributing the preference scores to sum
of a total of 100%, the relative importance of different
treatment attributes is shown in Figure 2 (item 2 is omit-
ted since not significant).
In additional evaluations, socio-demographic and struc-
tural parameters (age, gender, type of questionnaire)
were analysed. They influenced the preferences only
slightly. Therefore, the present model can be seen as a
general preference model for patients with Multiple
Myeloma independently from sociodemographic factors.
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Figure 2: DCE: Importance of therapy aspects; relative importance for decision
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The patients' view and desires in healthcare decisions
(e.g. attributes of therapies) are often not sufficiently
considered. However, in times of limited healthcare re-
sources,shareddecisionmakingaspatientsinvolvement
in treatment decisions have been encouraged in recent
years.Thisrequiresanunderstandingofpatients’priorit-
ies concerning treatment decision making.
The present study collects and depicts the preferences
of German MM-patients regarding their therapy. Based
on a qualitative study to ensure content validity, a
quantitative preference measurement was performed
including a direct assessment and a choice-based
measurement of patients’ preferences (DCE). This latter
techniqueallowstheestimationoftherelativeimportance
of different aspects of care and the trade-offs between
these aspects, while the direct assessment allows the
inclusion of more aspects. Hence, both methods should
be used in a combined way.
For practicability DCE needs to be performed with
preferably the least number of parameter and pairs. The
levelofcomplexityofourstudyturnedouttomanageable
for the participants.
The study population comprised 282 myeloma patients,
who completed paper-based and online-questionnaires.
The intense usage of the paper version shows that offer-
ing the paper copy is important and useful – at least in
this patient population.
Since the questionnaire was widely spread (paper and
pencilversionandonlineversion)thenumberofpatients
got into contact with the questionnaire is unknown –
therefore, response rates cannot be calculated. Study
participants are probably more committed and well-in-
formed than the average of MM-patients, because most
of the respondents were therapy-experienced and mem-
bers of patient advocacy groups. Furthermore study par-
ticipants are younger than the average MM-patients in
cancer registries. We do not know, if this selection could
have potentially biased the preference assessments.
However, the age of the patients was not associated with
the preference-model in our study.
As expected, the health status of the respondents in the
presenttrialwasclearlyundertheaverageoftheGerman
general population. The analysis revealed the greatest
differences concerning physical health aspects, the dis-
crepancies regarding mental health factors were less
pronounced. Obviously, patients with multiple myeloma
feel particularly limited in their physical abilities.
In the direct measurement of preferences, the study
participants prioritized 16 treatment aspects. Effective-
ness aspects including duration of effect and further
treatment options as “must haves” for registered com-
pounds are ranked highest by the patients. Maximal
prolonged life expectancy, minor side effects as well as
therapy-free intervals were also very important. Social
quality of life, cost aspects and the mode of application
(bythephysicianorself-application)werelessimportant.
In the simultaneous measurement of preferences (DCE;
eightpairswitheightaspects)“furthertreatmentoptions”
ranked highest, followed by “maximal prolongation of life
expectancy”. Provided that these two attributes were
given, patients clearly preferred the respective alterna-
tives.Thesefindingsarecongruentwiththedirectprefer-
ence evaluation,showing a high score for life expectancy
and further treatment options.
Furthermore,agoodemotionalqualityoflife(“Notalways
think of the disease”) and intervals between the treat-
ments – relieving the patients to some extent at least
temporarily – were also relevant for the decision. Self-
application of the treatment as well as physical quality
of life had an additional but minor influence. In the DCE
side effects did not reveal a significant impact and the
attribute “Social quality of life” could not be estimated.
Except the low rating of the aspects “Physical quality of
life”and“Sideeffects”intheDCEcomparedtothedirect
assessment,theresultsofthetwotechniqueswerewidely
congruent.
Conclusion
Besidesprolongationoflifeexpectancyandeffectiveness
of treatments, multiple myeloma patients are very con-
cerned, that the chosen therapy does not affect further
treatment options. In addition, therapy-free intervals as
well as an improved emotional well-being are valued as
very important, whereas no supplementary costs, treat-
ment by physician and self-application were ranked
comparatively low.
This study confirmed classical direct assessment of
preferences as well as the DCE method as valid survey
techniques for eliciting preferences of patients with mul-
tiple myeloma. Both methods should be used in a com-
binedway,sincethedirectassessmentisabletoconsider
more potentially important aspects, and the DCE forces
participantstoranktheseaspectsinacomplexdecision,
avoiding ceiling effects and “all-is-important” results.
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